Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

Abstract : Triple-negative breast cancer (TNBC) lacks targeted therapies and has a worse prognosis than other breast cancer subtypes, underscoring an urgent need for new therapeutic targets and strategies. IRE1 is an endoplasmic reticulum (ER) stress sensor, whose activation is predominantly linked to the resolution of ER stress and, in the case of severe stress, to cell death. Here we demonstrate that constitutive IRE1 RNase activity contributes to basal production of pro-tumorigenic factors IL-6, IL-8, CXCL1, GM-CSF, and TGF beta 2 in TNBC cells. We further show that the chemotherapeutic drug, paclitaxel, enhances IRE1 RNase activity and this contributes to paclitaxel-mediated expansion of tumor-initiating cells. In a xenograft mouse model of TNBC, inhibition of IRE1 RNase activity increases paclitaxel-mediated tumor suppression and delays tumor relapse post therapy. We therefore conclude that inclusion of IRE1 RNase inhibition in therapeutic strategies can enhance the effectiveness of current chemotherapeutics.
Complete list of metadatas

Cited literature [45 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01879955
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, July 16, 2019 - 5:15:47 PM
Last modification on : Wednesday, July 17, 2019 - 3:05:44 PM

File

s41467-018-05763-8.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Susan E. Logue, Eoghan P. Mcgrath, Patricia Cleary, Stephanie Greene, Katarzyna Mnich, et al.. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nature Communications, Nature Publishing Group, 2018, 9, pp.3267. ⟨10.1038/s41467-018-05763-8⟩. ⟨hal-01879955⟩

Share

Metrics

Record views

108

Files downloads

38